[1]CurrentPatentAssignee:GALAPAGOSNV-WO2014/139882,2014,A1
[2]CurrentPatentAssignee:GALAPAGOSNV-WO2014/139882,2014,A1
[3]Desroy,Nicolas;Housseman,Christopher;Bock,Xavier;Joncour,Agnès;Bienvenu,Natacha;Cherel,Laëtitia;Labeguere,Virginie;Rondet,Emilie;Peixoto,Christophe;Grassot,Jean-Marie;Picolet,Olivier;Annoot,Denis;Triballeau,Nicolas;Monjardet,Alain;Wakselman,Emanuelle;Roncoroni,Veronique;LeTallec,Sandrine;Blanque,Roland;Cottereaux,Celine;Vandervoort,Nele;Christophe,Thierry;Mollat,Patrick;Lamers,Marieke;Auberval,Marielle;Hrvacic,Boska;Ralic,Jovica;Oste,Line;VanderAar,Ellen;Brys,Reginald;Heckmann,Bertrand[JournalofMedicinalChemistry,2017,vol.60,#9,p.3580-3590]
[4]Gong,Ping;Jia,Fang;Jiang,Nan;Lei,Hongrui;Li,Changtao;Yang,Yu;Zhai,Xin[Organicprocessresearchanddevelopment,2020,vol.24,#6,p.997-1005]
[1]Patent:WO2014/139882,2014,A1
[2]JournalofMedicinalChemistry,2017,vol.60,p.3580-3590
[1]CurrentPatentAssignee:GALAPAGOS-WO2014/139882,2014,A1
[2]Desroy,Nicolas;Housseman,Christopher;Bock,Xavier;Joncour,Agnès;Bienvenu,Natacha;Cherel,Laëtitia;Labeguere,Virginie;Rondet,Emilie;Peixoto,Christophe;Grassot,Jean-Marie;Picolet,Olivier;Annoot,Denis;Triballeau,Nicolas;Monjardet,Alain;Wakselman,Emanuelle;Roncoroni,Veronique;LeTallec,Sandrine;Blanque,Roland;Cottereaux,Celine;Vandervoort,Nele;Christophe,Thierry;Mollat,Patrick;Lamers,Marieke;Auberval,Marielle;Hrvacic,Boska;Ralic,Jovica;Oste,Line;VanderAar,Ellen;Brys,Reginald;Heckmann,Bertrand[JournalofMedicinalChemistry,2017,vol.60,#9,p.3580-3590]
[1]CurrentPatentAssignee:GALAPAGOSNV-WO2014/139882,2014,A1
[2]Desroy,Nicolas;Housseman,Christopher;Bock,Xavier;Joncour,Agnès;Bienvenu,Natacha;Cherel,Laëtitia;Labeguere,Virginie;Rondet,Emilie;Peixoto,Christophe;Grassot,Jean-Marie;Picolet,Olivier;Annoot,Denis;Triballeau,Nicolas;Monjardet,Alain;Wakselman,Emanuelle;Roncoroni,Veronique;LeTallec,Sandrine;Blanque,Roland;Cottereaux,Celine;Vandervoort,Nele;Christophe,Thierry;Mollat,Patrick;Lamers,Marieke;Auberval,Marielle;Hrvacic,Boska;Ralic,Jovica;Oste,Line;VanderAar,Ellen;Brys,Reginald;Heckmann,Bertrand[JournalofMedicinalChemistry,2017,vol.60,#9,p.3580-3590]
[1]Gong,Ping;Jia,Fang;Jiang,Nan;Lei,Hongrui;Li,Changtao;Yang,Yu;Zhai,Xin[Organicprocessresearchanddevelopment,2020,vol.24,#6,p.997-1005]
[2]Desroy,Nicolas;Housseman,Christopher;Bock,Xavier;Joncour,Agnès;Bienvenu,Natacha;Cherel,Laëtitia;Labeguere,Virginie;Rondet,Emilie;Peixoto,Christophe;Grassot,Jean-Marie;Picolet,Olivier;Annoot,Denis;Triballeau,Nicolas;Monjardet,Alain;Wakselman,Emanuelle;Roncoroni,Veronique;LeTallec,Sandrine;Blanque,Roland;Cottereaux,Celine;Vandervoort,Nele;Christophe,Thierry;Mollat,Patrick;Lamers,Marieke;Auberval,Marielle;Hrvacic,Boska;Ralic,Jovica;Oste,Line;VanderAar,Ellen;Brys,Reginald;Heckmann,Bertrand[JournalofMedicinalChemistry,2017,vol.60,#9,p.3580-3590]
[3]CurrentPatentAssignee:GALAPAGOSNV-WO2014/139882,2014,A1Locationinpatent:Paragraph00362-00364;00469-00471
Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis.
Journal: Journal of medicinal chemistry 20170511
Title: Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.
Journal: The Journal of pharmacology and experimental therapeutics 20170101
Title: The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis.
Journal: European journal of pharmacology 20151015
Title: Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation.
Journal: American journal of respiratory and critical care medicine 20131015
Title: Lysophosphatidic acid (LPA) and its receptors: role in airway inflammation and remodeling.
Journal: Biochimica et biophysica acta 20130101
Title: Problems of the pathogenesis, clinics, and therapy of panarteritis of the aorta and its branches.
Journal: Cor et vasa 19750101
Title: Desroy N, et al. Discovery of 2-[-Ethyl-6---(3-hydroxyazetidin-1-yl)-2-oxoethylpiperazin-1-yl-8-methylimidazo,2-apyridin-3-ylmethylamino-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis. J Med Chem. 2017 May 11;60(9):3580-3590.
